New England Journal of Medicine· 2019Q1
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
- 3,618citations
- Q1SCImago
- 2019year
Short summary
Transcatheter aortic-valve replacement (TAVR) with a self-expanding bioprosthesis is non-inferior to surgical aortic-valve replacement in low-risk patients with severe aortic stenosis, showing comparable rates of death or disabling stroke at 24 months.
AI-generated from the title and abstract; the full text is not read.
Key points
- TAVR with a self-expanding supraannular bioprosthesis was compared to surgical aortic-valve replacement in low-risk patients with severe aortic stenosis.
- The primary end point was a composite of death or disabling stroke at 24 months.
- TAVR was non-inferior to surgery for this composite end point.
- The trial included 850 patients who reached 12-month follow-up, with analysis focused on 24-month outcomes.
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis who are at increased risk for death from surgery; less is known about TAVR in low-risk patients. METHODS: We performed a randomized noninferiority trial in which TAVR with a self-expanding supraannular bioprosthesis was compared with surgical aortic-valve replacement in patients who had severe aortic stenosis and were at low surgical risk. When 850 patients had reached 12-month follow-up, we analyzed data regarding the primary end point, a composite of death or disabling stroke at 24 months, using Bayesian methods. RESULTS: ). CONCLUSIONS: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months. (Funded by Medtronic; ClinicalTrials.gov number, NCT02701283.).
The authors' abstract, as published at the source. New England Journal of Medicine, 2019 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Cardiology and Cardiovascular Medicine
Cardiology and Cardiovascular MedicineMedicine